Arcutis Net Debt To E B I T D A from 2010 to 2024
| ARQT Stock | USD 12.69 0.44 3.59% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (0.52) | Current Value (0.54) | Quarterly Volatility 21.6619637 |
Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 31.2 M, Selling General Administrative of 182.2 M or Total Revenue of 62.6 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.0 or PTB Ratio of 2.65. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
Arcutis | Net Debt To E B I T D A |
Latest Arcutis Biotherapeutics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Arcutis Biotherapeutics over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Arcutis Biotherapeutics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcutis Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Arcutis Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (3.94) | |
| Geometric Mean | 1.70 | |
| Coefficient Of Variation | (549.86) | |
| Mean Deviation | 10.42 | |
| Median | 2.81 | |
| Standard Deviation | 21.66 | |
| Sample Variance | 469.24 | |
| Range | 84.8828 | |
| R-Value | (0.12) | |
| Mean Square Error | 497.81 | |
| R-Squared | 0.01 | |
| Significance | 0.66 | |
| Slope | (0.59) | |
| Total Sum of Squares | 6,569 |
Arcutis Net Debt To E B I T D A History
About Arcutis Biotherapeutics Financial Statements
Arcutis Biotherapeutics shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Arcutis Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcutis Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcutis Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (0.52) | (0.54) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.